Human medicines European public assessment report (EPAR): Tyruko, natalizumab, Multiple Sclerosis, R 17 oktober Human medicines European public assessment report (EPAR): Tyruko, natalizumab, Multiple Sclerosis, R Human medicines European public assessment report (EPAR): Tyruko, natalizumab, Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Date of authorisation: 22/09/2023, Status: Authorised Lees verder » Wil je het laatste nieuws in jouw mailbox? Meld je dan aan voor de nieuwsbrief.